North Clin Istanb. Ahead of Print: NCI-21976 | DOI: 10.14744/nci.2024.21976
2Núcleo de Pesquisa em Doenças Crônicas não Transmissíveis (NUPEN), School of Nutrition from the Federal University of Bahia, Salvador, Bahia, Brazil
Corresponding Author: Jozélio Freire de Carvalho
Manuscript Language: English
Risk of cancer and conventional syntethic DMARDS: A narrative review
Thelma Skare1, Jozélio Freire de Carvalho21Department of Rheumatology, Hospital Evangélico Mackenzie, Curitiba, PR, Brazil2Núcleo de Pesquisa em Doenças Crônicas não Transmissíveis (NUPEN), School of Nutrition from the Federal University of Bahia, Salvador, Bahia, Brazil
Immunosuppressors and immunomodulators are widely used for the treatment of rheumatic diseases. Among them are the conventional Disease-Modifying Antirheumatic Drugs (DMARDs) such as methotrexate, azathioprine, antimalarials, cyclosporine, etc. These drugs can induce remission or control inflammation, improving patients' outcomes. Nevertheless, there is some concern that these drugs may have a carcinogenic potential, favoring the appearance of tumors. Herein, a narrative review of malignancy risk after using conventional DMARDs is done. (NCI-2023-12-14)
Keywords: Cancer; disease-modifying antirheumatic drugs; DMARDs; immunosuppressive drugs.Corresponding Author: Jozélio Freire de Carvalho
Manuscript Language: English